Second-generation antipsychotic medications and risk of pneumonia in schizophrenia

Chian Jue Kuo, Shu Yu Yang, Ya Tang Liao, Wei J. Chen, Wen Chung Lee, Wen Yi Shau, Yao Tung Chang, Shang Ying Tsai, Chiao Chicy Chen

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

This study assessed the association between second-generation antipsychotic medications and risk of pneumonia requiring hospitalization in patients with schizophrenia because the evidence is limited in the population. We enrolled a nationwide cohort of 33 024 inpatients with schizophrenia ranged in age from 18 to 65 years, who were derived from the National Health Insurance Research Database in Taiwan from 2000 to 2008. Cases (n = 1741) were defined as patients who developed pneumonia after their first psychiatric admissions. Risk set sampling was used to match each case with 4 controls by age, sex, and the year of the first admission based on nested case-control study. Antipsychotic exposure was categorized by type, duration, and daily dose, and the association between exposure and pneumonia was assessed using conditional logistic regression. We found that current use of clozapine (adjusted risk ratio = 3.18, 95% CI: 2.62-3.86, P

Original languageEnglish
Pages (from-to)648-657
Number of pages10
JournalSchizophrenia Bulletin
Volume39
Issue number3
DOIs
Publication statusPublished - May 2013

Keywords

  • clozapine
  • dose-dependent
  • pneumonia
  • second-generation antipsychotics

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Second-generation antipsychotic medications and risk of pneumonia in schizophrenia'. Together they form a unique fingerprint.

  • Cite this

    Kuo, C. J., Yang, S. Y., Liao, Y. T., Chen, W. J., Lee, W. C., Shau, W. Y., Chang, Y. T., Tsai, S. Y., & Chen, C. C. (2013). Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophrenia Bulletin, 39(3), 648-657. https://doi.org/10.1093/schbul/sbr202